Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03037385
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:44.497707+00:00
Published At
2025-05-31T00:00:00+00:00
Record Updated At
2025-05-31
Results Posted At
2025-05-31
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["RET-altered Non Small Cell Lung Cancer", "Medullary Thyroid Cancer", "RET-altered Papillary Thyroid Cancer", "RET-altered Colon Cancer", "RET-altered Solid Tumors", "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Thyroid Diseases", "Thyroid Neoplasm", "Thyroid Cancer, Papillary", "Carcinoma, Neuroendocrine", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Neoplasms by Site", "Neoplasms", "Lung Diseases", "Respiratory Tract Disease", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Endocrine System Diseases", "Endocrine Gland Neoplasm", "Head and Neck Neoplasms", "Adenocarcinoma, Papillary", "Adenocarcinoma", "Carcinoma", "Neoplasms, Glandular and Epithelial", "Neoplasms by Histologic Type", "Neuroendocrine Tumors", "Neuroectodermal Tumors", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Colonic Neoplasms", "Colorectal Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Digestive System Disease", "Gastrointestinal Disease", "Colonic Diseases", "Intestinal Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-05-31"
protocolSection.identificationModule.nctId
"NCT03037385"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-05-31"

Study condition terms

  • RET-altered Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Medullary Thyroid Cancer (protocolSection.conditionsModule.conditions)
  • RET-altered Papillary Thyroid Cancer (protocolSection.conditionsModule.conditions)
  • RET-altered Colon Cancer (protocolSection.conditionsModule.conditions)
  • RET-altered Solid Tumors (protocolSection.conditionsModule.conditions)
  • Lung Neoplasm (protocolSection.conditionsModule.conditions)
  • Carcinoma, Non-Small-Cell Lung (protocolSection.conditionsModule.conditions)
  • Thyroid Diseases (protocolSection.conditionsModule.conditions)
  • Thyroid Neoplasm (protocolSection.conditionsModule.conditions)
  • Thyroid Cancer, Papillary (protocolSection.conditionsModule.conditions)
  • Carcinoma, Neuroendocrine (protocolSection.conditionsModule.conditions)
  • Respiratory Tract Neoplasms (protocolSection.conditionsModule.conditions)
  • Thoracic Neoplasms (protocolSection.conditionsModule.conditions)
  • Neoplasms by Site (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Lung Diseases (protocolSection.conditionsModule.conditions)
  • Respiratory Tract Disease (protocolSection.conditionsModule.conditions)
  • Carcinoma, Bronchogenic (protocolSection.conditionsModule.conditions)
  • Bronchial Neoplasms (protocolSection.conditionsModule.conditions)
  • Endocrine System Diseases (protocolSection.conditionsModule.conditions)
  • Endocrine Gland Neoplasm (protocolSection.conditionsModule.conditions)
  • Head and Neck Neoplasms (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma, Papillary (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Carcinoma (protocolSection.conditionsModule.conditions)
  • Neoplasms, Glandular and Epithelial (protocolSection.conditionsModule.conditions)
  • Neoplasms by Histologic Type (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Tumors (protocolSection.conditionsModule.conditions)
  • Neuroectodermal Tumors (protocolSection.conditionsModule.conditions)
  • Neoplasms, Germ Cell and Embryonal (protocolSection.conditionsModule.conditions)
  • Neoplasms, Nerve Tissue (protocolSection.conditionsModule.conditions)
  • Colonic Neoplasms (protocolSection.conditionsModule.conditions)
  • Colorectal Neoplasms (protocolSection.conditionsModule.conditions)
  • Intestinal Neoplasms (protocolSection.conditionsModule.conditions)
  • Gastrointestinal Neoplasms (protocolSection.conditionsModule.conditions)
  • Digestive System Neoplasm (protocolSection.conditionsModule.conditions)
  • Digestive System Disease (protocolSection.conditionsModule.conditions)
  • Gastrointestinal Disease (protocolSection.conditionsModule.conditions)
  • Colonic Diseases (protocolSection.conditionsModule.conditions)
  • Intestinal Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.